A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1689-1697

  Yasuda, Kazuto ^a   Ranade, Aarati ^b   Venkataramanan, Raman ^b   Strom, Stephen ^b   Chupka, Jonathan ^c   Ekins, Sean ^d,e,f   Schuetz, Erin ^a   Bachmann, Kenneth ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

^d Collaborations in Chemistry ^*  (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFRADINE; CEFUROXIME; CLINDAMYCIN; CYTOCHROME P450 3A4; DEMECLOCYCLINE; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; GRISEOFULVIN; LINCOSAMIDE; MINOCYCLINE; NAFCILLIN; PENICILLIN V; PREGNANE X RECEPTOR; RIFAMPICIN; SULFAFURAZOLE; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE; TROLEANDOMYCIN;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTESTINE; LIVER; MOLECULAR DOCKING; PHARMACOPHORE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CELL LINE; CYTOCHROME P-450 CYP3A; DNA PRIMERS; ENZYME INDUCTION; GENES, REPORTER; HUMANS; INTESTINES; LIVER; RECEPTORS, STEROID; RNA, MESSENGER;

EID: 47949085749     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020701     Document Type: Article

References (60)

1. Atkinson A, Kenny JR, and Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647.
2. Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, and Sambucetti L (2004) PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res 50:237-246.
3. Back DJ, Grimmer SF, Orme ML, Proudlove C, Mann RD, and Breckenridge AM (1988) Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 25:527-532.
4. Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, and Orme M (1991) The lack of interaction between temafloxacin and combined oral contraceptive steroids. Contraception 43:317-323.
5. Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, Hendrix CW, and Flexner C (1999) The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 65:428-438.
6. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95:12208-12213.
7. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J, Jr., van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
8. Bud R (2007) Antibiotics: the epitome of a wonder drug. BMJ 334 (Suppl 1):s6.
9. Chang C, Bahadduri PM, Polli JE, Swaan PW, and Ekins S (2006) Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976-1984.
10. Cizman M (2003) The use and resistance to antibiotics in the community. Int J Antimicrob Agents 21:297-307.
11. Cropp JS and Bussey HI (1997) A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 17:917-928.
12. Cynke E, Binet I, Haefeli WE, and Thiel G (1999) Flucloxacillin and cyclosporine: an unrecognised but relevant interaction in renal transplant recipients (Abstract). Kidney Int 55:1156.
13. de Groot MJ (2006) Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 11:601-606.
14. DeRossi SS and Hersh EV (2002) Antibiotics and oral contraceptives. Dent Clin North Am 46:653-664.
15. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, Konig J, Dorje F, Murdter TE, Ackermann A, Dormann H, et al. (2007) Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46:1039-1049.
16. Ekins S and Erickson JA (2002) A pharmacophore for human pregnane-X-receptor ligands. Drug Metab Dispos 30:96-99.
17. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, et al. (2007) Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592-603.
18. Ekins S, Johnston JS, Bahadduri P, D'Souzza VM, Ray A, Chang C, and Swaan PW (2005a) In vitro and pharmacophore based discovery of novel hPEPT1 inhibitors. Pharm Res 22:512-517.
19. Ekins S, Kirillov E, Rakhmatulin EA, and Nikolskaya T (2005b) A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab Dispos 33:474-481.
20. Eng JV, Marcus R, Hadler JL, Imhoff B, Vugia DJ, Cieslak PR, Zell E, Deneen V, McCombs KG, Zansky SM, et al. (2003) Consumer attitudes and use of antibiotics. Emerg Inf Dis 9:1128-1135.
21. Finch CK, Chrisman CR, Baciewicz AM, and Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162:985-992.
22. Friedman CI, Huneke AL, Kim MH, and Powell J (1980) The effect of ampicillin on oral contraceptive effectiveness. Obstet Gynecol 55:33-37.
23. Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, et al. (2007) Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37:124-138.
24. Harmsen S, Meijerman I, Beijnen JH, and Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369-380.
25. Huwyler J, Wright MB, Gutmann H, and Drewe J (2006) Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab 7:119-126.
26. Joshi JV, Joshi UM, Sankholi GM, Krishna U, Mandlekar A, Chowdhury V, Hazari K, Gupta K, Sheth UK, and Saxena BN (1980) A study of interaction of low-dose combination oral contraceptive with ampicillin and metronidazole. Contraception 22:643-652.
27. Khandelwal A, Krasowski MD, Reschly EJ, Sinz M, Swaan PW and Ekins S (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol, in press.
28. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92:73-82.
29. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
30. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, and Strom SC (1999) The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887-894.
31. Kovacs GT, Riddoch G, Duncombe P, Welberry L, Chick P, Weisberg E, Leavesley GM, and Baker HW (1989) Inadvertent pregnancies in oral contraceptive users. Med J Aust 150:549-551.
32. Kramer B, Rarey M, and Lengauer T (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37:228-241.
33. Krstenansky PM, Jones WN, and Garewal HS (1987) Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm 6:804-806.
34. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, and Lee TC (2003) Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol 55:588-590.
35. LeCluyse EL (2001) Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 134:283-289.
36. Lemaire G, Benod C, Nahoum V, Pillon A, Boussioux AM, Guichou JF, Subra G, Pascussi JM, Bourguet W, Chavanieux A, et al. (2007) Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol Pharmacol 72:572-581.
37. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton GA, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
38. Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, and Sutcliffe MJ (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by co-medications commonly used by patients with cancer. Drug Metab Dispos 34:534-538.
39. McConn DJ, 2nd, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
40. Moore JT and Kliewer SA (2000) Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1-10.
41. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275: 15122-15127.
42. Pai MP, Momary KM, and Rodvold KA (2006) Antibiotic drug interactions. Med Clin North Am 90:1223-1255.
43. Piscitelli SC and Gallicano KD (2001) Interactions among drugs for HIV and opportunistic infections. N Engl J Med 344:984-996.
44. Reimers D and Jezek A (1971) The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives. Prax Pneumol 25:255-262.
45. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748.
46. Rosenfeld JM, Vargas R Jr, Xie W, and Evans RM (2003) Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282.
47. Schuetz EG, Schinkel AH, Relling MV, and Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 93:4001-4005.
48. Schuster D and Langer T (2005) The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 45:431-439.
49. Shenfield GM and Griffin JM (1991) Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 20:15-37.
50. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
51. Sparrow MJ (1989) Pregnancies in reliable pill takers. N Z Med J 102:575-577.
52. Strom S, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods in Enzymology 272:388-401.
53. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
54. van Dijke CP and Weber JC (1984) Interaction between oral contraceptives and griseofulvin. Br Med J 288:1125-1126.
55. Watkins RE, Davis-Searles PR, Lambert MH, and Redinbo MR (2003) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815-828.
56. Weaver K and Glasier A (1999) Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 59:71-78.
57. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
58. Wynalda MA, Hutzler JM, Koets MD, Podoll T, and Wienkers LC (2003) In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 31:878-887.
59. Yao C and Levy RH (2002) Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 91:1923-1935.
60. Zhang T, Zhou JH, Shi LW, Zhu RX, and Chen MB (2007) 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Bioorg Med Chem Lett 17:2156-2160.